Role of Xuesaitong in Amelioration of Neural Function and Alteration of Bax Expression in Rats with Brain Trauma

Traumatic brain injury (TBI) is one of the most common diseases in clinical neurosurgery characterized with high incidence rate, mortality and many complications. Objectives: The purpose of this study is to explore the roles of Xuesaitong in the therapeutic effect of brain trauma and alteration of expression in Bax, a kind of promoting apoptosis factor. Methods: The rat traumatic brain injury models were established by using modified free falling body impact method. Thereafter, Xuesaitong was employed to be administered to TBI rats, and NSS Score Rating Scale was used to evaluate the effect of Xuesaitong. Moreover, real-time PCR was used to detect the Bax expression changes before and after the Xuesaitong administration. Results: Xuesaitong could accelerate the neurofunctional recovery of TBI rats, accompanied by NSS Scores significant decrease. Simultaneously, it also could inhibit the expression of Bax factor. Conclusions: Xusaitong could markedly ameliorate TBI restoration, in which it promotes the neurofunctional recovery, and at the same time it inhibits the expression of Bax.

Meta-analysis of the effect of Xuesaitong combined with edaravone on hemorheological indexes in patients with acute cerebral infarction

Objective:To systematically evaluate the effect of Xuesaitong injection combined with edaravone injection on hemorheology indexes in patients with acute cerebral infarction.Methods:Search CNKI,WanFang,VIP,SinoMed,PubMed,Cochrane Library and other databases,collect randomized controlled trials(RCTs)of Xuesaitong combined with edaravone in the treatment of acute cerebral infarction from the establishment of the database to November 2020,using RevMan 5.3 software Perform Meta analysis.Results:10 RCTs were included,with a total of 834 patients,417 in the experimental group and 417 in the control group.The results of Meta analysis showed that the experimental group was better than the control group in improving the whole plasma viscosity(MD=-0.73,95%CI[-0.83,-0.63],P<0.00001);in terms of improving the thrombosis coefficient,the test group is better than the control group(MD=-0.19,95%CI[-0.22,-0.15],P<0.00001);In terms of platelet aggregation rate,the test group was better than the control group(MD=-0.21,95%CI[-0.25,-0.17],P<0.00001).GRADE systematically evaluates whole plasma viscosity,thrombosis coefficient,and platelet aggregation rate,showing that the level of evidence is low or very low,and the strength of the recommendation is weak.Conclusion:Xuesaitong injection combined with edaravone injection has relatively satisfactory results in improving hemorheology indexes in patients with acute cerebral infarction,and there is no obvious safety problem.However,due to the small number of included studies and the total sample size,and the limitation of the quality of the included original studies,the results of this study need to be designed with strict,high-quality,large-sample,multi-center,and more internationally recognized clinical outcome indicators and efficacy experiments to verify,in order to obtain stronger evidence-based medicine.

Stability of Xuesaitong capsules in gastrointestinal lavage fluid

Objective:To obtain a formulation with high bioavailability through evaluation of the stability of three types of Xuesaitong capsules in the stomachs and intestines of rats.We compared the stability of the Panax notoginsenoside R1 as well as the ginsenosides Rg1,Rb1,Re,and Rd in different formulations.Methods:Artificial stomach fluid(ASF)and artificial intestinal fluid(AIF)were prepared.Stability of three types of Xuesaitong capsules was examined for 4 h in stomachs and 24 h in intestines.Samples were analyzed at different times by high-performance liquid chromatography.Percent content of NGR1,GRg1,GRb1,GRe,and GRd at different times was calculated.Results:Hard capsules incubated in ASF disintegrated within 2e3 min,whereas soft capsules disintegrated within 7e8 min.Components in hard capsules were dissolved rapidly in water,with content of each compound reaching 90%in 5 min,and degradation of each compound reaching 30e50%after incubation for 240 min.Dissolution and degradation of each component in soft capsules with a water-soluble base tended to balance at 30 e90 min.Contents in soft capsules with a lipid-soluble base showed slow dissolution after ASF incubation for 120 min.Five saponins in identical types of capsules incubated in ASF had similar stability curves.Contents of hard capsules and soft capsules with a watersoluble base degraded rapidly within 30 min and reached a plateau when Xuesaitong capsules were incubated in AIF.

The study on the mechanism of Sodium aescinate combined with Xuesaitong for cerebral thrombosis treatment

Objective:To observe the mechanism of Sodium aescinate combined with Xuesaitong for cerebral thrombosis treatment and offer clinical help to cerebral thrombosis treatment. Methods:A total of 92 patients with cerebral thrombosis were selected and randomly divided into groups: the observation group (46 people) and the control group (46 people).The patient in the control group were treated with conventional therapy and the patients in the observation group were treated with Sodium aescinate combined with Xuesaitong on the basis of conventional therapy. Inflammatory factors (IL-6, IL-10, TNF-α and CRP), Nerve cell factor (NSE, NGF and NTF) and blood rheology indexes (Fg, BVH, BVL and PV) were detected and analyzed before and after treatment.Results:The comparison of inflammatory factors, Nerve cell factor and blood rheology indexes in the two groups before treatment were not statistically significant. Inflammatory factors (IL-6, TNF-α and CRP), Nerve cell factor (NSE) and blood rheology indexes (Fg, BVH, BVL and PV) in both groups after treatment significantly decreased compared with that before treatment. Inflammatory factors (IL-10), Nerve cell factor (GF and NTF) in both groups after treatment significantly increased compared with that before treatment. The changes were statistically significant. Inflammatory factors (IL-6, TNF-α and CRP), Nerve cell factor (NSE) and blood rheology indexes (Fg, BVH, BVL and PV) in observation group after treatment decreased more significantly than that in control group, and inflammatory factors (IL-10), Nerve cell factor (GF and NTF) increased more significantly than that in control group. The difference between two groups was considered statistically significant.Conclusion:Sodium aescinate combined with Xuesaitong could inhibit the inflammatory reaction, improve the blood flow condition and promote rehabilitation in patients with cerebral thrombosis. So it has a very important clinical significance of the treatment to cerebral hemorrhage.

Meta analysis of Xuesaitong injection in the treatment of angina pectoris of coronary heart disease

Objective:To evaluate the efficacy and safety of Xuesaitong Injection in the treatment of angina pectoris.Methods:CNKI and WAN were retrieved Fang,VIP,CBMdisc,PubMed and Cochrane libraries published a randomized controlled trial of Xuesaitong Injection in the treatment of angina pectoris of coronary heart disease from the beginning of the establishment of the database to January 2020.29 cases were finally included in the study through layer by layer selection.The total sample size was 2560 cases,including 1307 cases in the experimental group and 1253 cases in the control group.The data collected were meta analyzed by Revman 5.3 software.Results:on the basis of routine western medicine treatment,Xuesaitong injection was added in the clinical comprehensive effective rate([RR=1.31;95%CI(1.25,1.39)]),angina symptom improvement rate([RR=1.16;95%CI(1.07,1.26)]),ECG improvement rate([RR=1.25;95%CI(1.14,1.38)]),angina attack times([RR=-2.49;95%CI(-3.27,-1.70)]);fibrinogen([MD=-0.61;95%CI(-0.77,-0.45)]),plasma(specific)viscosity([MD=-0.19;95%CI(-0.22,-0.16)]),hematocrit([MD=-0.04;95%CI(-0.05,-0.03)])and other aspects were superior to the conventional treatment of Western medicine,the difference was statistically significant.Safety aspect:the reported adverse reactions were mild and tolerable events such as headache,dizziness,flush,etc.,no serious adverse events,and no separation from the report was found.Conclusion:on the basis of conventional western medicine,Xuesaitong injection can effectively improve the clinical efficacy,and has a high safety.However,due to the low quality of the included study and the small sample size,there is a potential bias in the study;therefore,the application and promotion of the research conclusions need to be cautious,and need to be further verified by more large sample,multicenter,double-blind clinical randomized controlled trials.

Effect of Xuesaitong Combined with Autologous Platelet-rich Gel on Blood Glucose,AT-III,TNF-αand 24-h Urinary Protein Level in Patients with Diabetic Foot

[Objectives]To investigate the clinical effect of different doses of Xuesaitong combined with autologous platelet-rich gel(APG)on patients with diabetic foot(DF).[Methods]90 patients with diabetic foot admitted to our hospital from February 2017 to February 2019 were enrolled in the study.According to the random number table method,the subjects were divided into study group A and B and control group C.Group A was given a low dose of Xuesaitong combined with APG,while group B was given high-dose Xuesaitong combined with APG and group C was treated only with APG.Patients in the three groups were observed and the changes of related indexes were detected.[Results]After treatment,with regard to the three groups,the fasting blood glucose,2-h postprandial blood glucose level,HbA1c,TNF-α,Hcy,blood urea nitrogen(BUN),creatinine(Cr)and 24-h urine protein levels were all decreased,yet AT-III level was increased,and granulation tissue coverage and thickness,wound clearance rate were increased,while the repair time of ulcer surface was significantly reduced.The above indexes were all significantly different(P<0.05).Compared with the control group C,the changes of the indexes in the study group A and B were the same as above,and the difference was significant(P<0.05).Compared with the study group A,the level of AT-III in group B was significantly increased(P<0.05),while TNF-α,Hcy,BUN,Cr and 24-h urine protein levels were significantly decreased(P<0.05).There was no significant difference in the other indexes between groups A and B(P>0.05).[Conclusions]Xuesaitong combined with APG could effectively reduce the blood sugar level of DF patients,improve the clinical indexes,promote wound healing,and the high-dose group had more significant advantages and was worthy of promotion.

Chinese preparation Xuesaitong promotes the mobilization of bone marrow mesenchymal stem cells in rats with cerebral infarction

After cerebral ischemia, bone marrow mesenchymal stem cells are mobilized and travel from the bone marrow through peripheral circulation to the focal point of ischemia to initiate tissue regeneration. However, the number of bone marrow mesenchymal stem cells mobilized into peripheral circulation is not enough to exert therapeutic effects, and the method by which blood circulation is promoted to remove blood stasis influences stem cell homing. The main ingredient of Xuesaitong capsules is Panax notoginseng saponins, and Xuesaitong is one of the main drugs used for promoting blood circulation and removing blood stasis. We established rat models of cerebral infarction by occlusion of the middle cerebral artery and then intragastrically administered Xuesaitong capsules(20, 40 and 60 mg/kg per day) for 28 successive days. Enzyme-linked immunosorbent assay showed that in rats with cerebral infarction, middle- and high-dose Xuesaitong significantly increased the level of stem cell factors and the number of CD117-positive cells in plasma and bone marrow and significantly decreased the number of CD54-and CD106-positive cells in plasma and bone marrow. The effect of low-dose Xuesaitong on these factors was not obvious. These findings demonstrate that middle- and high-dose Xuesaitong and hence Panax notoginseng saponins promote and increase the level and mobilization of bone marrow mesenchymal stem cells in peripheral blood.

Effect of Xuesaitong Soft Capsule (血塞通软胶囊) on Hemorrheology and in Auxiliarily Treating Patients with Acute Cerebral Infarction

Objective: To observe the therapeutic effect of Xuesaitong soft capsule(血塞通软胶囊, XST)and its effect on platelet counts, coagulation factor 1 (CF1) as well as hemorrheologic indexes in treating patients with acute cerebral infarction (ACI). Methods: Two hundred and four patients with ACI were assigned into two groups, the control group (n=96) and the treated group (n=108). They were all treated with conventional Western medicines, including mannitol, troxerutin, citicoline, piracetam and aspirin, while to the treated group, XST was given additionally through oral intake, twice a day, 2 capsules each time for 8 successive weeks. The clinical efficacy was evaluated according to the nerve function deficits scoring and the changes of platelet count. CF1 and hemorrheological indexes were measured before and after treatment.Results: The total effective rate was 87.0% in the treated group, and 87.5% in the control group, respectively, showing insignificant difference between them. But the markedly effective rate in the treated group ( 66.7%) was significantly higher than that in the control group (27.1%, P<0.01). The count of platelet was not changed significantly in both groups after treatment, while CF1 in them evidently lowered at the end of the 4th and 8th weeks of treatment, but showed insignificant difference between the two groups. The hematocrit, whole blood viscosity and plasma viscosity in both groups were all improved significantly after treatment, but also showed insignificant difference in comparison of the two groups. Conclusion: XST has good efficacy in auxiliary treatment of patients with ACI, though its mechanism remains to be further explored.

Clinical Observation of the Effect of Xuesaitong Soft Capsule (血塞通软胶囊) on Post-hepatitis Fibrosis

Objective: To study the effect of Xuesaitong soft capsule (血塞通软胶囊, XST) on liver fibrosis criteria in patients with post-hepatitis fibrosis. Methods: Sixty-four patients with such fibrosis were randomly divided into the treated group and control group. They were treated with XST and Dahuang Zhechong pill (大黄NFDA1虫丸) for 3 months respectively. Their liver fibrosis criteria were examined before and after treatment. Results: The levels of serum procollagen Ⅲ, hyaluronic acid, collagen Ⅳ, laminin in the two groups were significantly lower ( P <0.01) than those before treatment. The differences between the two groups were insignificant ( P >0.05). Conclusion: XST could recover liver dysfunction and had anti-liver fibrosis function.

Study of Interference Treatment by Xuesaitong (血塞通) Soft Capsuleon Patients of Nephrosis Syndrome with Qi Deficiency and Blood Stasisduring Dose Reducing Stage of Corticosteroid

Objective: To observe the effect of Xuesaitong (血塞通, XST) soft capsule in interference treatment on patients of nephrosis syndrome (NS) during corticosteroid (CS) dose reducing stage. Methods:Seventy-one NS patients applying prednisone and initiating dose reducing stage were randomized into trial group and control group. On the basis of conventional prednisone dose reduction of both groups, the trial group was given additionally XST, and the treatment course ended with the reduction to maintenance dose. In the course of observation, those who did not comply with the criteria of observation were excluded. Before and after the dose reduction, TCM syndrome scoring, 24 hrs urinary protein amount, blood β2-microglobulin (β2-MG), urinary β2-MG, blood fibrinogen (Fbg), plasma prothrombin time (PT), blood lipid, etc. were observed. Results: The trial group of XST could obviously lower their urinary protein amount and blood lipid level (P＜0.05 or P＜0.01), markedly improve the blood coagulation parameters (P＜0.01), improve the TCM syndrome and CS induced adverse reaction (P＜0.05 or P＜0.01), also obviously reduced the recurrence rate of NS (P＜0.05). Conclusion: XST could obviously improve the clinical symptoms and renal impairment parameters in NS patients during CS dose reduction stage, improve the CS induced adverse reaction and prevent the recurrence of NS.

Attenuation of Brain Inflammatory Response after Focal Cerebral Ischemia/Reperfusion with Xuesaitong Injection (血塞通注射液) in Rats

Objective: To investigate the neuro-protective effect of Xuesaitong Injection (血塞通注射液, XST) on brain inflammatory response after transient focal cerebral ischemia/reperfusion in rats. Methods: Focal cerebral ischemia/reperfusion models of male rats were induced by transient occlusion for 2 h of middle cerebral artery (MCA) which was followed by 24 h reperfusion. XST was administered through intraperitoneal injection of 25 mg/kg or 50 mg/kg at 4 h after the onset of ischemia. After reperfusion for 24 h, the neurological function score was evaluated, the brain edema was detected with dry-wet weight method, the myeloperoxidase (MPO) activity and the expression of intercellular adhesion molecule-1(ICAM-1) of ischemic cerebral cortex and caudate putamen was determined by spectrophotometry and immunohistochemistry respectively. Results: XST not only lowered neurological function score at the dose of 50 mg/kg, but reduced brain edema and inhibited MPO activity and ICAM-1 expression as compared with the ischemia/reperfusion model group (P<0.01).Conclusion: XST has a definite effect on inhibiting the expression of ICAM-1 and neutrophil infiltration in rats with cerebral ischemia/reperfusion when treatment started at 4 h after ischemia onset, and also attenuates inflammation in the infarcted cerebral area.

血塞通联合甲磺酸倍他司汀治疗后循环缺血性眩晕患者的影响

目的:探讨血塞通联合甲磺酸倍他司汀治疗后循环缺血性眩晕患者的影响。方法:选取2022年1月至2023年6月在南京市中医院全科门诊治疗的160例后循环缺血性眩晕患者,随机将患者分为西药组和中西联合药物组,每组各纳入80例,西药组患者采用甲磺酸倍他司汀治疗,中西联合药物组采用血塞通联合甲磺酸倍他司汀治疗,两组患者均持续治疗2周。比较两组患者治疗前后临床症状采用眩晕评估评分量表(DARS)、眩晕障碍调查量表(DHI)和眩晕病临床证候评价量表评估、血液流变学包括血浆黏度(PV)、全血黏度(WVB)和全血纤维蛋白原(FIB),脑血流动力学包括左椎动脉(LVA)、右椎动脉(RVA)、基底动脉(BA)和阻力系数(RI)变化,并记录两组患者治疗期间的不良反应发生情况。结果:治疗后,中西联合药物组患者的DARS、DHI量表评分和眩晕病临床证候评价量表评分均较西药组低,差异有统计学意义(P<0.05);中西联合药物组PV、WVB和FIB水平均较西药组低,差异有统计学意义(P<0.05);中西联合药物组LVA、RVA和BA水平较西药组高,RI水平较西药组低,差异有统计学意义(P<0.05)。中西联合药物组寒战、心悸、皮疹、恶心呕吐不良反应率为10.00%,西药组为6.25%,差异无统计学意义(P>0.05)。结论:血塞通联合甲磺酸倍他司汀治疗后循环缺血性眩晕患者可以改善患者临床疗效,降低患者的血压黏稠度,并有效调节患者脑血流动力循环。

血塞通注射液联合气压治疗仪在脑梗死偏瘫患者中的应用效果

目的:观察血塞通注射液联合气压治疗仪在脑梗死偏瘫患者中的应用效果。方法:选取2020年8月至2022年9月该院收治的103例脑梗死偏瘫患者进行前瞻性研究,按随机数字表法将其分为对照组51例与观察组52例。对照组采用气压治疗仪治疗,观察组在对照组基础上联合血塞通注射液治疗,比较两组下肢深静脉血栓发生率,治疗前后股静脉血流水平、凝血功能指标[凝血酶原时间(PT)、活化部分凝血酶原时间(APTT)、D-二聚体(D-D)]水平、肢体运动功能[Fugl-Meyer运动功能量表(FMA)]评分、神经功能缺损程度[美国国立卫生研究院卒中量表(NIHSS)]评分,以及不良反应发生率。结果:观察组下肢深静脉血栓发生率为5.77%(3/52),低于对照组的21.57%(11/51),差异有统计学意义(P<0.05);治疗后,两组股静脉血流平均速度、血流峰速度均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组PT、APTT均长于对照组,且观察组长于对照组,两组D-D水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组FMA评分均高于治疗前,且观察组高于对照组,两组NIHSS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗期间,两组均未发生明显不良反应。结论:血塞通注射液联合气压治疗仪预防脑梗死偏瘫患者下肢深静脉血栓效果显著,可改善凝血功能指标水平,降低神经功能缺损程度,提高运动功能,其效果优于单纯气压治疗仪治疗。

Effect of Ningxin decoction,Xuesaitong,rosuvastatin on inflammatory cytokines and atherosclerotic plaque of ApoE^-/- mice

Objective Through the establishment of atherosclerosis model in Apo E-/- mice to investigate the effects of Ningxin Decoction,Xuesaitong and rosuvastatin on serum lipid,inflammatory factors and plaque structure.Methods Feed 80 Apo E-/- mice aged 8 weeks with high-fat diet for 4 weeks at first.Eighty rats were randomly divid-

Protective effects of combination of Xuesaitong and aspirin on cerebral ischemia and reperfusion injury in rats

Objective:To investigate the protective effects of the combination of Xuesaitong(XST)and aspirin on cerebral ischemia and reperfusion injury(CIRI)in rats,and further explore the underlying mechanisms.Methods:A total of 150 male Sprague-Dawley(SD)rats were randomly divided into five groups with 30rats in each group:sham group,middle cerebral artery occlusion/reperfusion(MCAO/R)model group,XST group,aspirin group,and XST+aspirin group.Rats were pretreated with XST,aspirin,or XST+aspirin for7 d.One hour after the last administration,a model of CIRI was induced by MCAO/R.Neurological deficits were assessed using Longa’s five-point scale.Cerebral edema was detected by the measurement of brain water content.The volume of cerebral infarction was determined by 2,3,5-triphenyltetrazolium chloride(TTC)staining.The activities of superoxide dismutase(SOD),catalase(CAT),and glutathione peroxidase(GSH-Px),as well as levels of malonaldehyde(MDA)were detected by commercial kits.Enzyme-linked immunosorbent assay(ELISA)was used to determine the levels of interleukin-1(),interleukin-4(IL-4),interleukin-6(IL-6),interleukin-10(IL-10),tumor necrosis factor-alphamonocyte chemotactic protein 1(MCP-1),and kynurenine in serum,cerebral cortex,and hippocampus of MCAO/R rats.The protein expression of nuclear factor erythroid 2-related factor(Nrf2),heme oxygenase-1(HO-1),I-kappa B alpha(IκBα),and nuclear factor kappa B(B)/p65 in the cortex were analyzed by western blotting.Results:Treatment of XST,aspirin,and XST+aspirin significantly alleviated the neurological deficits,cerebral edema,and cerebral infarct volume induced by MCAO/R.Treatment of XST,aspirin,and XST+aspirin also reduced MDA,,MCP-1,and kynurenine levels,and increased SOD,CAT,GSH-Px,IL-4,and IL-10 levels in serum,cerebral cortex,and hippocampus of MCAO/R rats.Furthermore,treatment of XST,aspirin,and XST+aspirin decreased the expression of nuclearB/p65 and increased the expression of IκBα,nuclear Nrf2,and HO-1.Importantly,the combination of XST and aspirin enhanced the protective effects of XST or aspirin treatment alone on CIRI in rats.Conclusion:The combination of XST and aspirin significantly inhibited oxidative stress and inflammation in serum,cerebral cortex,and hippocampus of MCAO/R rats.The combination of XST and aspirin exerted more protective effects than XST or aspirin treatment alone.The combination of XST and aspirin might provide the synergistic therapeutic effects on CIRI,and deserve further clinical investigation.

血塞通注射液治疗中风的快速卫生技术评估

目的 利用快速卫生技术评估(rHTA)方法评估血塞通注射液治疗中风的有效性、安全性和经济性,为临床合理用药提供参考。方法 检索万方医学网、中国生物医学文献数据库、中国知网、PubMed、Cochrane Library、Embase等数据库以及国际卫生技术评估网络、国际卫生技术评估协会等网站,对血塞通注射液治疗中风的HTA报告、Meta分析/系统评价、药物经济学研究等资料进行汇总分析。结果 共纳入29篇文献,其中14篇为Meta分析/系统评价、15篇为药物经济学研究,未检索到HTA报告。Meta分析/系统评价结果显示,血塞通注射液治疗中风在提高总有效率、改善临床症状及相关量表评分等方面与空白对照组及部分药物对照组相比具有一定优势。安全性研究显示,血塞通注射液不良反应以过敏样反应为主。药物经济学评价的结果差异较大,可能与各项研究之间时间跨度较长、部分药物价格有所调整相关。结论 血塞通注射液治疗中风有助于提高临床疗效,改善评价指标,但存在部分严重不良反应,且与部分化学药相比经济性并不占优势。

尤瑞克林联合血塞通治疗脑栓塞的效果及对血液流变学的影响

目的:探讨尤瑞克林联合血塞通治疗脑栓塞的效果及对血液流变学的影响。方法:选取2020年9月-2022年7月佳木斯市中心医院收治的90例脑栓塞患者,使用随机数字表法将其分为观察组和对照组,各45例。对照组接受血塞通治疗,观察组接受尤瑞克林联合血塞通治疗,对比两组治疗总有效率、血流动力学指标、颈动脉内膜中层厚度及颈动脉斑块面积、炎症因子指标、神经功能缺损评分、日常生活能力评分。结果:观察组治疗总有效率(95.56%)高于对照组(82.22%),差异有统计学意义(P<0.05)。治疗前,两组纤维蛋白原(FIB)、红细胞压积(HCT)、血小板凝集指数、血浆黏度(PV)、颈动脉内膜中层厚度、颈动脉斑块面积、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素-6(IL-6)比较,差异均无统计学意义(P>0.05);治疗后,两组各项指标均降低,观察组均低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组美国国立卫生研究院卒中量表(NIHSS)评分及日常生活活动能力量表(ADL)评分差异均无统计学意义(P>0.05);治疗后,两组的NIHSS评分均降低,观察组低于对照组,ADL评分均升高,观察组高于对照组,差异均有统计学意义(P<0.05)。结论:尤瑞克林联合血塞通可有效改善脑栓塞患者的机体血液流变学指标,缩小颈动脉内膜中层厚度及斑块面积,缓解炎症反应,减轻神经功能缺损,提高日常生活能力,效果优异。

血塞通软胶囊对不稳定性心绞痛患者血管内皮功能及炎性因子的影响

目的研究血塞通软胶囊对不稳定性心绞痛患者血管内皮功能及炎性因子相关指标的影响。方法选取2020年1月—2021年3月期间河南省中医院心病科收治的心血瘀阻证不稳定性心绞痛住院患者176例,按随机数字表法分为试验组和对照组,每组各88例。两组患者均采取西医常规治疗,必要情况下可含服硝酸甘油片,试验组除常规西药外同时服用血塞通软胶囊。治疗15 d后,观察比较两组患者临床疗效,治疗前后血管内皮功能指标[肱动脉血流介导的血管舒张功能(Flow-mediated dilation,FMD)、单核细胞趋化因子(Monocyte chemotactic protein 1,MCP-1)、可溶性血管细胞间黏附分子(Soluble vascular cell adhesion molecule-1,sVCAM-1)、内皮素-1(Endothelin-1,ET-1)、一氧化氮(Nitric Oxide,NO)]以及血清炎性因子[白介素6(Interleukin 6,IL-6)、白介素10(Interleukin 10,IL-10)、高敏C反应蛋白(High-sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子α(Tumor necrosis factor alpha,TNF-α)、血清可溶性CD40配体(Soluble CD40 ligand,sCD40L)]水平。结果治疗后试验组总有效率92.05%(81/88)明显优于对照组总80.68%(71/88),差异有统计学意义(P<0.05)。治疗后试验组中医证候疗效总有效率93.18%(82/88)明显优于对照组78.55%(70/88),差异有统计学意义(P<0.01)。治疗后两组患者血清IL-6、hs-CRP、sCD40L及TNF-α水平均较治疗前降低,IL-10水平均较治疗前升高,差异有统计学意义(P<0.05);且试验组血清IL-6、hs-CRP、sCD40L及TNF-α水平低于对照组,IL-10水平明显高于对照组,差异有统计学意义(P<0.05)。治疗后两组患者ET-1、MCP-1、sVCAM-1水平均较治疗前降低,NO、FMD水平均较治疗前升高,差异有统计学意义(P<0.05);且试验组血清ET-1、MCP-1、sVCAM-1水平低于对照组,NO、FMD水平高于对照组,差异有统计学意义(P<0.05)。治疗期间,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论血塞通软胶囊对于心血瘀阻证的不稳定性心绞痛患者具有良好的临床治疗效果,与抑制局部炎症反应以及改善患者内皮功能相关。

血塞通软胶囊联合西药治疗血瘀型冠心病不稳定型心绞痛的临床效果

目的:探讨西医联合血塞通软胶囊治疗血瘀型冠心病不稳定型心绞痛效果。方法:选择2020年9月—2021年5月河南省中医院收治的血瘀型冠心病不稳定型心绞痛患者68例作为研究对象,按随机数字表法分为对照组与研究组,各34例。对照组接受冠心病西医常规治疗,研究组在对照组基础上口服血塞通软胶囊治疗,比较两组心绞痛改善情况、临床疗效、心功能及生活质量。结果:治疗后,两组心绞痛发作次数、发作持续时间、甘油三酯用量均优于治疗前,研究组优于对照组,差异有统计学意义(P<0.05);两组临床疗效总有效率高于对照组,差异有统计学意义(P<0.001);治疗后,两组左室收缩末期容积指数(LVSDVI)、左室舒张末期容积指数(LVEDVI)均降低,左室射血分数(LVEF)、二尖瓣环心室充盈早期血流速度峰值(E峰)与晚期心室充盈心房收缩血流速度峰值(A峰)比值(E/A)均升高,LVSDVI、LVEDVI均低于对照组,LVEF、E/A均高于对照组,差异有统计学意义(P<0.05);治疗后,两组生理机能、社会功能、精神健康及情感职能评分均升高,研究组高于对照组,差异有统计学意义(P<0.05)。结论:血塞通软胶囊联合西药治疗血瘀型冠心病不稳定型心绞痛,可以有效改善患者心功能,提高生活质量,治疗效果显著。

血塞通颗粒治疗急性冠脉综合征颈动脉斑块的效果

目的观察血塞通颗粒治疗急性冠脉综合征(acute coronary syndrome,ACS)患者颈动脉斑块的效果。方法选取102例ACS伴颈动脉粥样硬化患者,随机均分为对照组与观察组。在常规抗ACS治疗的基础上,对照组服用阿托伐他汀钙片20 mg,每日1次;观察组在对照组治疗的基础上加用血塞通颗粒,每次50 mg,每日3次,疗程为12周。比较2组治疗前后血压、血脂、颈动脉内-中膜厚度(carotid artery-media thickness,IMT)、斑块情况、动态动脉硬化指数(ambulatory arterial stiffness index,AASI)及改良Crouse斑块评分,检测血清炎症因子、血液流变学及血管内皮功能指标。结果治疗后,2组的收缩压、舒张压及高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)比较差异均无统计学意义,但观察组的总胆固醇(total cholesterol,TC)、三酰甘油(triacylglycerol,TG)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)水平均低于对照组(P<0.05)。治疗后,观察组的IMT和斑块数量、面积、厚度及AASI、改良Crouse评分均低于对照组(P<0.05)。治疗后,观察组的血清一氧化氮(nitric oxide,NO)高于对照组,血清超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白细胞介素-6(interleukin-6,IL-6)、基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、内皮素-1(endothelin-1,ET-1)、P选择素(P-selectin,P-Sel)、血栓素B2(thromboxane B2,TXB2)及全血黏度(高切、低切)、血浆黏度及红细胞压积均低于对照组(P<0.05)。结论血塞通颗粒治疗ACS能缓解炎症反应、保护血管内皮功能及改善血液流变学,有效缩小ACS患者的颈动脉粥样硬化斑块并降低斑块易损性。